Top Page
BioInvent International AB
(BINV)
BioInvent International AB (BINV) vs. iShares MSCI Sweden ETF (EWD)
BioInvent International AB Business Overview & Revenue Model
BioInvent International AB Earnings Call Summary
BioInvent International AB Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 254.29M | 44.69M | 71.46M | 326.13M | 19.38M | 147.37M |
| Gross Profit | 254.29M | 44.69M | 71.46M | 326.13M | 19.38M | 147.37M |
| EBITDA | -301.77M | -409.38M | -312.71M | -27.13M | -263.32M | -63.99M |
| Net Income | -291.95M | -429.38M | -330.30M | -34.09M | -278.96M | -76.67M |
Balance Sheet | ||||||
| Total Assets | 916.67M | 989.24M | 1.40B | 1.71B | 1.45B | 802.64M |
| Cash, Cash Equivalents and Short-Term Investments | 797.52M | 867.16M | 1.07B | 1.02B | 1.08B | 729.27M |
| Total Debt | 12.94M | 17.41M | 23.24M | 26.96M | 28.37M | 11.60M |
| Total Liabilities | 105.93M | 103.42M | 90.45M | 106.09M | 80.32M | 59.14M |
| Stockholders Equity | 810.74M | 885.82M | 1.31B | 1.61B | 1.37B | 743.50M |
Cash Flow | ||||||
| Free Cash Flow | -255.56M | -390.50M | -355.00M | -53.60M | -259.10M | -69.32M |
| Operating Cash Flow | -248.58M | -380.47M | -341.69M | -41.23M | -245.84M | -62.62M |
| Investing Cash Flow | 206.37M | 564.35M | 59.68M | -628.85M | -467.54M | -6.70M |
| Financing Cash Flow | -8.79M | -8.46M | 23.14M | 273.49M | 894.87M | 644.62M |
BioInvent International AB Technical Analysis
BioInvent International AB Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | kr2.04B | 7.61 | 114.45% | ― | 1265.46% | ― | |
| ― | $1.83B | -6.27 | -36.52% | ― | 533.73% | 20.92% | |
| ― | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
| ― | €1.09B | ― | -41.54% | ― | ― | 0.57% | |
| ― | kr2.63B | ― | -55.23% | ― | -92.57% | -7.72% | |
| ― | kr3.51B | -3.77 | ― | ― | 20.12% | 40.54% | |
| ― | kr592.94M | ― | -275.87% | ― | ― | 38.99% |
BioInvent International AB Corporate Events
BioInvent International AB’s recent earnings call highlighted a mixed sentiment, reflecting both strategic advancements and financial challenges. The company demonstrated a strong focus on its lead programs, resulting in positive clinical outcomes and a notable increase in sales for the first nine months of the year. However, the quarter was marked by decreased sales and rising operating costs, culminating in negative financial results.
BioInvent International AB is a biotechnology company focused on developing novel immuno-modulatory antibodies for cancer therapy, aiming to enhance the efficacy of existing treatments and activate anti-cancer immunity in non-responding patients.
BioInvent International AB announced a strategic shift to prioritize its advanced clinical programs, BI-1206 and BI-1808, aiming to accelerate their development and enhance value creation. The company is set to achieve several key milestones in the second half of 2025, including additional data releases for its treatments targeting cutaneous T-cell lymphoma and non-Hodgkin’s lymphoma, as well as a Phase 2a study for solid tumors. This strategic focus is expected to strengthen BioInvent’s position in the immuno-oncology sector and potentially impact stakeholders positively by advancing promising cancer therapies.
The most recent analyst rating on (SE:BINV) stock is a Hold with a SEK29.00 price target. To see the full list of analyst forecasts on BioInvent International AB stock, see the SE:BINV Stock Forecast page.
BioInvent International AB has announced an upcoming presentation of its interim report for January to September 2025, scheduled for October 29, 2025. The presentation will be led by CEO Martin Welschof and CFO Stefan Ericsson, providing insights into the company’s financial performance and ongoing clinical programs. Stakeholders can participate via webcast or teleconference, highlighting BioInvent’s commitment to transparency and engagement with investors and analysts.
The most recent analyst rating on (SE:BINV) stock is a Hold with a SEK29.00 price target. To see the full list of analyst forecasts on BioInvent International AB stock, see the SE:BINV Stock Forecast page.
BioInvent International AB and Transgene have announced positive clinical results for their oncolytic virus BT-001, which shows promising antitumoral activity in combination with pembrolizumab in patients with advanced refractory tumors. The data presented at the ESMO 2025 Annual Meeting indicate that BT-001 is well tolerated and effective in shrinking tumors, supporting further development across a range of solid tumors. This development could enhance treatment options for cancer patients, particularly those with limited alternatives, by transforming cold tumors into immunologically active ones.
The most recent analyst rating on (SE:BINV) stock is a Hold with a SEK29.00 price target. To see the full list of analyst forecasts on BioInvent International AB stock, see the SE:BINV Stock Forecast page.
BioInvent International AB and Transgene have announced the presentation of translational data and updated clinical results for their oncolytic virus BT-001 at the ESMO 2025 Annual Meeting. The Phase 1 study results indicate that BT-001, in combination with pembrolizumab, shows promise as a treatment for advanced refractory tumors, demonstrating tumor shrinkage in both injected and non-injected lesions. This development could enhance the response to immune checkpoint inhibitors in refractory patients, potentially impacting the company’s position in the cancer immunotherapy market.
The most recent analyst rating on (SE:BINV) stock is a Hold with a SEK29.00 price target. To see the full list of analyst forecasts on BioInvent International AB stock, see the SE:BINV Stock Forecast page.
BioInvent International AB has initiated a Phase 2a clinical trial for its drug candidate BI-1206, in combination with pembrolizumab, targeting advanced or metastatic non-small cell lung cancer (NSCLC) and uveal melanoma. This trial follows promising results from Phase 1, where BI-1206 demonstrated safety and clinical activity, offering hope for overcoming resistance mechanisms in cancer treatment and potentially expanding its use across various indications where pembrolizumab is approved.
The most recent analyst rating on (SE:BINV) stock is a Hold with a SEK29.00 price target. To see the full list of analyst forecasts on BioInvent International AB stock, see the SE:BINV Stock Forecast page.
BioInvent International AB announced that it will present updated Phase 1 clinical data for BI-1910, a TNFR2 agonist for treating solid tumors, at the upcoming Society for Immunotherapy of Cancer (SITC) Annual Meeting. Despite the successful completion of the single agent dose escalation phase without notable adverse events, BioInvent has decided to pause the development of BI-1910 following a strategic review to focus on advancing other programs, such as BI-1808 and BI-1206. The announcement highlights BioInvent’s strategic shift and its potential implications for stakeholders, as TNFR2 represents a promising target for cancer immunotherapy.
The most recent analyst rating on (SE:BINV) stock is a Hold with a SEK29.00 price target. To see the full list of analyst forecasts on BioInvent International AB stock, see the SE:BINV Stock Forecast page.
BioInvent International AB announced that Vincent Ossipow has stepped down from its Board of Directors, effective immediately. Ossipow, who served on the board from 2016-2020 and 2021-2025, was praised for his leadership and contributions during critical growth phases. The board remains quorate with seven elected members, aligning with the company’s strategic focus on clinical development, which Ossipow endorses as beneficial for patients.
The most recent analyst rating on (SE:BINV) stock is a Buy with a SEK90.00 price target. To see the full list of analyst forecasts on BioInvent International AB stock, see the SE:BINV Stock Forecast page.
BioInvent International AB is a biotechnology company specializing in the development of novel immuno-modulatory antibodies for cancer therapy, with a focus on enhancing the efficacy of existing cancer treatments and activating anti-cancer immunity. In its latest earnings report, BioInvent highlighted significant progress in its clinical programs, particularly BI-1808 and BI-1206, which are advancing through various phases of clinical trials. The company reported a substantial increase in net sales to SEK 198.1 million for Q2 2025, driven by a USD 20 million transaction with XOMA Royalty. This financial boost has allowed BioInvent to focus on its most promising clinical assets, with several key data readouts expected in the coming years. Looking ahead, BioInvent remains committed to advancing its lead programs, with management expressing confidence in the potential of BI-1808 and BI-1206 to deliver impactful results in oncology, supported by strategic collaborations and a strong financial position.
BioInvent International AB has announced strategic changes to its portfolio, focusing on advancing its lead clinical programs, BI-1808 and BI-1206, which are in Phase 2a development for various cancers. The company aims to accelerate these programs towards key clinical milestones and regulatory approval, while pausing other early-stage developments and implementing a workforce reduction. This strategic shift is expected to enhance value creation and extend the company’s cash resources into Q1 2027, supporting future growth and maximizing patient and shareholder value.
The most recent analyst rating on (SE:BINV) stock is a Hold with a SEK41.00 price target. To see the full list of analyst forecasts on BioInvent International AB stock, see the SE:BINV Stock Forecast page.
BioInvent International AB has announced strategic changes to focus on its most advanced clinical assets, aiming to maximize patient impact and shareholder value. The company has several upcoming milestones, including data releases for its BI-1808 and BI-1206 programs, which could significantly impact its positioning in the immuno-oncology field.
The most recent analyst rating on (SE:BINV) stock is a Hold with a SEK41.00 price target. To see the full list of analyst forecasts on BioInvent International AB stock, see the SE:BINV Stock Forecast page.